Rigvir Group is a leading brand committed to providing access to virotherapy globally, with the aim of saving and improving the lives of cancer patients. Since 2002, Rigvir Group, comprised of several companies, has been at the forefront of developing oncolytic virotherapy. Their strategy focuses on the production of the unique oncolytic ECHO-7 virus Rigvir, as well as maintaining an efficient R&D team and sophisticated manufacturing processes.

As pioneers in the field, Rigvir Group was the first to register an oncolytic virus and systematically train healthcare professionals for its clinical use. This experience makes them the most experienced organization in the development and clinical practice of oncolytic viruses. Their mission is to invent, develop, and provide access to advanced biotechnological products that transform the treatment paradigm in oncology, ensuring the effective fight against cancer while prioritizing patient safety.

In recent years, Rigvir Group has transitioned into a biotech company, focusing on enhancing biotechnological manufacturing excellence. They have implemented functional changes and increased manufacturing capacity, allowing for global partnerships in product promotion and distribution. Rigvir Group has earned recognition from various organizations for their research and innovation, intellectual property management, and business performance.

As part of their commitment to patients, they have supported social projects through the Aina Muceniece Virotherapy Foundation